Stock listing
NASDAQ:CTXR Citius Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of Citius Pharmaceuticals, Inc.
Follow Citius Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CTXR
$0.509 USD -0.002 (-0.4%)
Close on Nov 20, 2026
- Day range
- $0.481 – $0.514 USDNov 20, 2026
- Volume
- 183,702 sharesNov 20, 2026
- Market cap
- $13.96M USDAt the close on Nov 20, 2026 · price × 27.45M shares outstanding
- 52-week range
- $0.370 – $1.540 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $151,992 USDMedian day 209,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CTXR · Home | $0.509 USD | -0.002 (-0.4%) | 183,702 | $0.481 | $0.514 | $0.481 | $0.511 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CTXR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.509 | -0.002 | -0.4% | $0.481 | $0.514 | $0.481 | 183,702 | |
| $0.511 | -0.008 | -1.6% | $0.530 | $0.530 | $0.500 | 65,395 | |
| $0.519 | -0.009 | -1.7% | $0.512 | $0.539 | $0.503 | 117,023 | |
| $0.528 | -0.008 | -1.4% | $0.545 | $0.545 | $0.500 | 150,672 | |
| $0.535 | +0.003 | +0.5% | $0.540 | $0.544 | $0.496 | 173,130 | |
| $0.532 | +0.052 | +10.8% | $0.475 | $0.571 | $0.461 | 650,807 | |
| $0.481 | -0.012 | -2.5% | $0.491 | $0.500 | $0.481 | 176,573 | |
| $0.493 | -0.033 | -6.4% | $0.529 | $0.545 | $0.476 | 302,133 | |
| $0.526 | -0.019 | -3.4% | $0.538 | $0.572 | $0.510 | 265,436 | |
| $0.545 | -0.012 | -2.2% | $0.590 | $0.595 | $0.531 | 199,456 | |
| $0.557 | +0.006 | +1.2% | $0.564 | $0.597 | $0.520 | 366,318 | |
| $0.551 | -0.022 | -3.9% | $0.562 | $0.571 | $0.542 | 138,079 | |
| $0.573 | +0.011 | +2.0% | $0.560 | $0.573 | $0.520 | 98,272 | |
| $0.562 | +0.039 | +7.4% | $0.528 | $0.570 | $0.520 | 372,737 | |
| $0.523 | -0.040 | -7.1% | $0.564 | $0.564 | $0.521 | 99,493 | |
| $0.563 | +0.022 | +4.1% | $0.525 | $0.610 | $0.484 | 402,870 | |
| $0.541 | +0.040 | +7.9% | $0.500 | $0.550 | $0.480 | 201,084 | |
| $0.502 | +0.052 | +11.6% | $0.442 | $0.525 | $0.408 | 521,722 | |
| $0.449 | +0.046 | +11.5% | $0.404 | $0.470 | $0.395 | 370,063 | |
| $0.403 | +0.032 | +8.6% | $0.377 | $0.410 | $0.370 | 435,300 | |
| $0.371 | -0.025 | -6.3% | $0.390 | $0.391 | $0.370 | 340,000 | |
| $0.396 | -0.022 | -5.3% | $0.410 | $0.413 | $0.394 | 383,600 | |
| $0.418 | -0.010 | -2.3% | $0.434 | $0.436 | $0.418 | 187,900 | |
| $0.428 | -0.032 | -7.0% | $0.460 | $0.469 | $0.414 | 526,900 | |
| $0.460 | 0.000 | 0.0% | $0.460 | $0.475 | $0.460 | 141,000 | |
| $0.460 | -0.005 | -1.1% | $0.460 | $0.487 | $0.460 | 303,100 | |
| $0.465 | -0.011 | -2.3% | $0.462 | $0.470 | $0.450 | 233,600 | |
| $0.476 | -0.017 | -3.4% | $0.481 | $0.500 | $0.460 | 192,800 | |
| $0.493 | -0.006 | -1.2% | $0.490 | $0.510 | $0.480 | 119,700 | |
| $0.499 | +0.010 | +2.0% | $0.490 | $0.510 | $0.480 | 144,200 | |
| $0.489 | -0.012 | -2.4% | $0.490 | $0.521 | $0.480 | 132,400 | |
| $0.501 | +0.020 | +4.2% | $0.489 | $0.510 | $0.488 | 161,700 | |
| $0.481 | -0.039 | -7.5% | $0.520 | $0.526 | $0.480 | 419,100 | |
| $0.520 | -0.012 | -2.3% | $0.522 | $0.540 | $0.520 | 132,600 | |
| $0.532 | -0.008 | -1.5% | $0.533 | $0.549 | $0.525 | 80,500 | |
| $0.540 | +0.009 | +1.7% | $0.546 | $0.568 | $0.530 | 154,800 | |
| $0.531 | -0.024 | -4.3% | $0.560 | $0.569 | $0.530 | 127,400 | |
| $0.555 | +0.006 | +1.1% | $0.550 | $0.560 | $0.550 | 150,300 | |
| $0.549 | -0.030 | -5.2% | $0.570 | $0.590 | $0.526 | 279,500 | |
| $0.579 | +0.009 | +1.6% | $0.570 | $0.596 | $0.567 | 65,200 | |
| $0.570 | +0.001 | +0.2% | $0.570 | $0.585 | $0.560 | 154,400 | |
| $0.569 | -0.029 | -4.8% | $0.604 | $0.610 | $0.569 | 223,100 | |
| $0.598 | +0.021 | +3.6% | $0.570 | $0.607 | $0.570 | 214,900 | |
| $0.577 | -0.023 | -3.8% | $0.587 | $0.602 | $0.572 | 155,300 | |
| $0.600 | +0.012 | +2.0% | $0.600 | $0.604 | $0.583 | 280,300 | |
| $0.588 | +0.028 | +5.0% | $0.571 | $0.600 | $0.571 | 245,000 | |
| $0.560 | 0.000 | 0.0% | $0.560 | $0.575 | $0.560 | 139,300 | |
| $0.560 | -0.013 | -2.3% | $0.580 | $0.585 | $0.560 | 129,000 | |
| $0.573 | -0.008 | -1.4% | $0.580 | $0.590 | $0.570 | 209,300 | |
| $0.581 | -0.004 | -0.7% | $0.586 | $0.595 | $0.581 | 153,800 | |
| $0.585 | +0.003 | +0.5% | $0.600 | $0.610 | $0.581 | 165,000 | |
| $0.582 | -0.019 | -3.2% | $0.601 | $0.610 | $0.581 | 76,500 | |
| $0.601 | +0.013 | +2.2% | $0.581 | $0.617 | $0.580 | 310,500 | |
| $0.588 | -0.014 | -2.3% | $0.602 | $0.610 | $0.580 | 299,600 | |
| $0.602 | +0.022 | +3.8% | $0.585 | $0.614 | $0.585 | 250,600 | |
| $0.580 | +0.011 | +1.9% | $0.563 | $0.590 | $0.563 | 222,100 | |
| $0.569 | -0.011 | -1.9% | $0.580 | $0.590 | $0.569 | 226,200 | |
| $0.580 | -0.022 | -3.7% | $0.580 | $0.593 | $0.570 | 280,900 | |
| $0.602 | -0.027 | -4.3% | $0.619 | $0.630 | $0.590 | 361,600 | |
| $0.629 | +0.052 | +9.0% | $0.577 | $0.650 | $0.577 | 824,800 | |
| $0.577 | -0.027 | -4.5% | $0.596 | $0.610 | $0.570 | 442,500 | |
| $0.604 | +0.029 | +5.0% | $0.578 | $0.670 | $0.578 | 2,160,400 | |
| $0.575 | -0.025 | -4.2% | $0.610 | $0.610 | $0.570 | 392,900 | |
| $0.600 | 0.000 | 0.0% | $0.605 | $0.613 | $0.600 | 159,400 | |
| $0.600 | -0.038 | -6.0% | $0.637 | $0.643 | $0.571 | 588,500 |
Splits
2 splits since 2017 · NASDAQ:CTXR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation | |
| 1-for-15 | Consolidation |
- Ticker
- NASDAQ:CTXR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 11, 2026
Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
Latest deck · Dec 1, 2025
Investor Presentation (December 2025)
Investor deck · 28 slides
Latest news
Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
Nov 11, 2026
Closed $0.481 (-2.5%) on Nov 11, 2026
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
Oct 26, 2026
Closed $0.449 (+11.5%) on Oct 26, 2026
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
Oct 12, 2026
Closed $0.493 (-1.2%) on Oct 12, 2026
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
Sep 3, 2026
Closed $0.602 (+3.8%) on Sep 3, 2026
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
Aug 12, 2026
Closed $0.765 (+6.3%) on Aug 12, 2026
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
Aug 5, 2026
Closed $0.781 (+25.4%) on Aug 5, 2026
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
Jul 21, 2026
Closed $0.546 (+13.5%) on Jul 21, 2026
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Jun 1, 2026
Closed $0.634 (-3.2%) on Jun 1, 2026
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
May 26, 2026
Closed $0.697 (-0.6%) on May 26, 2026
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
May 15, 2026
Closed $0.527 (-24.7%) on May 18, 2026
Citius Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 29 in the last 12 months · 152 in all · newest Nov 11, 2026 · oldest 2019
- Decks
- 27 decks · latest Dec 1, 2025
Where Citius Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CTXR · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CTXR | BOATS | United States | USD |
| gettex:47N0 | gettex | Germany | EUR |
| Lang & Schwarz:A40MD0 | Lang & Schwarz | Germany | EUR |
| Frankfurt:47N0 | Frankfurt | Germany | EUR |
| Munich:47N0 | Munich | Germany | EUR |
Valuation
Price/book 0.2× against a median of 0.9×: the lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$3.05M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.71
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. · NASDAQ:CTXR | US$13.96M | −US$3.05M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 1.71 |
| Hepion Pharmaceuticals, Inc. · OTC:HEPA | US$14.63M | US$10.37M | n/a | n/a | n/a | n/a | n/a | n/a | -1.02 |
| Vectorite Biomedical, Inc. · TPEX:4170 | US$14.21M | US$9.16M | 4.9× | 4.9× | n/a | 0.9× | 156.6% | 0.0× | n/a |
| Estrella Immunopharma, Inc. · NASDAQ:ESLA | US$14.11M | US$14.01M | n/a | n/a | n/a | n/a | n/a | n/a | 1.31 |
| TaiwanJ Pharmaceuticals Co., Ltd. · TPEX:6549 | US$13.69M | US$11.86M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| Actuate Therapeutics, Inc. · NASDAQ:ACTU | US$13.60M | US$11.50M | n/a | n/a | n/a | n/a | n/a | n/a | 1.75 |
| BeyondSpring, Inc. · NASDAQ:BYSI | US$13.57M | US$12.99M | 0.3× | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| Acumen Pharmaceuticals, Inc. · NASDAQ:ABOS | US$13.49M | −US$38.84M | n/a | n/a | n/a | 0.4× | n/a | 0.8× | 1.45 |
| Pharma Equity Group A/S Class A · OMXCOP:PEG | US$13.47M | US$15.05M | n/a | n/a | 52.7× | 3.6× | n/a | 0.4× | n/a |
| BioInvent International AB · OMXSTO:BINV | US$13.45M | −US$6.62M | n/a | −1.7× | n/a | 0.7× | n/a | 0.1× | n/a |
| Thalia Therapeutics PLC · LSE:THAT | US$13.36M | US$11.39M | n/a | 1,199× | n/a | 4.2× | n/a | 0.0× | n/a |
| Median of the others | US$13.59M | US$11.45M | 2.6× | 4.9× | 52.7× | 0.9× | 156.6% | 0.0× | 1.31 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.00 USD · Analysts' mean
- EPS, year to Sep 2026
- -2.03 · 1 analyst
- Revenue, year to Sep 2026
- 10.05M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Leonard Mazur | Co-Founder, CEO and Chairman of the Board of Directors |
| Jaime Bartushak | Chief Financial Officer & Chief Business Officer |
| Alan Lader | SVP, Head of Clinical Operations and Quality Assurance |
| Catherine Kessler | EVP, Regulatory Affairs |
| Gary F. Talarico | EVP, Operations |
| Jay Wadekar | SVP, Business Strategy |
| Kelly Creighton | EVP, Chemistry, Manufacturing and Controls |
| Kevin Carey | VP, Program & Alliance Management |
| Michael McGuire | VP, Commercial |
| Myron S. Czuczman | Chief Medical Officer and EVP |
| Nikolas Burlew | EVP, Quality Assurance |
| Myron Holubiak | Co-Founder, Executive Vice Chairman |
Board
| Director | Role |
|---|---|
| Leonard Mazur | Co-Founder, CEO and Chairman of the Board of Directors |
| Carol Webb | Director |
| Dennis M. McGrath | Director |
| Eugene Holuka | Director |
| Myron Holubiak | Co-Founder, Executive Vice Chairman |
| Robert Smith | Director |
| Suren Dutia | Director |
Events
- Next results
- Dec 22, 2026 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Aug 14, 2026 · After close | −25.7% |
| Q2 2026 | May 15, 2026 · After close | −24.7% |
| Q1 2026 | Feb 13, 2026 | −6.4% |
| Q4 2025 | Dec 23, 2025 · After close | −23.0% |
| Q3 2025 | Aug 12, 2025 · After close | −1.5% |
| Q2 2025 | May 14, 2025 · After close | −11.7% |
| Q1 2025 | Feb 12, 2025 · Before open | −0.4% |
| Q4 2024 | Dec 27, 2024 · After close | +6.3% |
| Q3 2024 | Aug 12, 2024 · After close | −11.7% |
| Q2 2024 | May 14, 2024 · After close | −9.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Feb 14, 2024 · After close | +9.1% |
| Q4 2023 | Dec 29, 2023 · After close | +6.9% |
| Q3 2023 | Aug 14, 2023 · After close | −6.7% |
| Q2 2023 | May 12, 2023 · After close | −9.2% |
| Q1 2023 | Feb 10, 2023 · After close | −9.3% |
| Q4 2022 | Dec 22, 2022 · After close | −18.0% |
| Q3 2022 | Aug 11, 2022 · After close | −1.7% |
| Q2 2022 | May 12, 2022 · After close | −0.3% |
| Q1 2022 | Feb 10, 2022 · After close | 0.0% |
| Q4 2021 | Dec 15, 2021 · After close | −5.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (December 2025) | Investor deck | 28 slides | Dec 1, 2025 |
| Investor Presentation (October 2025) | Investor deck | 26 slides | Oct 23, 2025 |
| Investor Presentation (March 2025) | Investor deck | 24 slides | March 2025 |
| Investor Presentation (January 2025) | Investor deck | 27 slides | January 2025 |
| SPAC Merger (October 2023) | SPAC merger | 33 slides | Oct 24, 2023 |
| Investor Presentation (September 2023) | Investor deck | 28 slides | September 2023 |
| Investor Presentation (June 2023) | Investor deck | 29 slides | June 2023 |
| Investor Presentation (February 2023) | Investor deck | 30 slides | February 2023 |
| 64th American Society of Hematology (ASH) Annual Meeting 2022 | Conference | 19 slides | Dec 11, 2022 |
| Investor Presentation (December 2022) | Investor deck | 30 slides | December 2022 |
All 27 decks
Financings
| Raise | Date |
|---|---|
| Registered direct offering of shares of common stock (or pre-funded warrants) Closed: US$5M raised · US$0.985 a share · Warrants at US$0.86 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Commercial launch of LYMPHIR including milestone and regulatory payments, development of product candidates, and general corporate purposes | Apr 27, 2026 |
| Registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants Closed: US$6M raised · US$1.51 a share · Warrants at US$1.4 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Support the commercial launch of LYMPHIR, including milestone and regulatory payments, development of product candidates, and general corporate purposes | Oct 21, 2025 |
| Registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) and accompanying short-term warrants Closed: US$6M raised · US$1.22 a share · Warrants at US$1 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Support the commercial launch of LYMPHIR, including milestone, regulatory and other payments, and general corporate purposes | Jun 12, 2025 |
| Registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) Announced: about US$2M · US$1.15 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Support the commercial launch of LYMPHIR and general corporate purposes | Apr 1, 2025 |
| Registered direct offering of shares of common stock and accompanying warrants Announced: about US$3M · US$4.035 a share · Warrants at US$3.91 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: General corporate purposes, including pre-clinical and clinical development of product candidates, working capital and capital expenditures | Jan 8, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.0K | 90.0K | 90.0K | 90.0K | 75.0K | 50.0K | ||||
| Cost of revenue | 75.0K | 50.0K | 45.0K | |||||||
| Gross profit | 0 | 0 | ||||||||
| Research and development | 9.16M | 11.9M | 14.8M | 17.7M | 12.2M | 8.81M | 8.60M | 6.56M | 2.94M | 2.93M |
| Operating income | -38.5M | -42.0M | -36.7M | -33.3M | -23.5M | -17.7M | -15.6M | -13.8M | -9.99M | -7.45M |
| Depreciation and amortization | 1.43K | 2.67K | 2.92K | 1.49K | 844 | 893 | 1.75K | 2.63K | 1.34K | |
| EBITDA | -42.0M | -36.7M | -33.3M | -23.5M | -17.7M | -15.6M | -13.8M | -9.98M | -7.45M | |
| Interest expense | 267.8K | 10.8K | 15.7K | 16.4K | 15.8K | 850.8K | 8.99K | |||
| Income before tax | -38.7M | -38.8M | -32.0M | -33.1M | -23.1M | -17.5M | -15.6M | 12.5M | 10.4M | -8.30M |
| Income tax | 1.06M | 576.0K | 576.0K | 576.0K | 1.23K | 741 | ||||
| Net income | -37.4M | -40.2M | -32.5M | -33.6M | -23.1M | -17.5M | -15.6M | -12.5M | -10.4M | -8.30M |
| Earnings per share, basic | -3.38 | -5.97 | -5.57 | -0.23 | -0.23 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 |
| Earnings per share, diluted | -3.38 | -5.97 | -5.57 | -0.23 | -0.23 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.25M | 3.25M | 26.5M | 41.7M | 70.1M | 13.9M | 7.89M | 9.18M | 3.20M | 294.4K |
| Inventory | 22.3M | 8.27M | ||||||||
| Current assets | 27.9M | 14.2M | 34.4M | 44.6M | 72.8M | 14.0M | 7.94M | 10.1M | 3.42M | 892.8K |
| Property, plant and equipment | 1.43K | 4.10K | 7.02K | 1.58K | 590 | 1.48K | 3.24K | 3.74K | ||
| Goodwill | 9.35M | 9.35M | 9.35M | 9.35M | 9.35M | 9.35M | 9.35M | 1.59M | 1.59M | 1.59M |
| Total assets | 130.9M | 116.7M | 103.6M | 114.0M | 142.4M | 43.8M | 36.7M | 31.1M | 24.4M | 22.0M |
| Accounts payable | 13.7M | 4.93M | 2.93M | 1.17M | 1.28M | 1.86M | 2.71M | 1.57M | 602.4K | 909.2K |
| Current liabilities | 44.9M | 35.8M | 5.78M | 4.53M | 3.98M | 4.10M | 4.61M | 3.18M | 2.47M | 5.18M |
| Total liabilities | 53.4M | 42.5M | 12.2M | 10.6M | 9.65M | 10.1M | 9.59M | |||
| Shareholders' equity | 67.6M | 70.1M | 90.8M | 102.8M | 132.2M | 33.7M | 27.2M | 30.6M | 21.9M | 16.8M |
| Shares outstanding | 18.1M | 7.25M | 6.35M | 146.2M | 146.0M | 55.6M | 28.9M | 16.2M | 8.35M | 4.88M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -26.6M | -28.2M | -29.1M | -28.4M | -24.3M | -16.9M | -12.4M | -11.3M | -7.97M | -5.90M |
| Capital spending | -6.94K | -1.83K | -2.13K | |||||||
| Free cash flow | -24.3M | -16.9M | -7.97M | |||||||
| Cash from investing | -5.75M | -5.00M | -40.0M | -1.83K | -2.13K | 255.7K | ||||
| Cash from financing | 33.3M | 9.97M | 13.8M | 120.5M | 22.9M | 11.1M | 17.3M | 10.9M | 5.26M | |
| Change in cash | 1.00M | -23.2M | -15.2M | -28.4M | 56.2M | 5.97M | -1.29M | 5.98M | 2.91M | -381.8K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 4, 2026 | Current report | SEC |
| 8-K · Current report | Oct 26, 2026 | Results | SEC |
| 8-K · Current report | Aug 21, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Aug 10, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 5, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 4, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jun 3, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| CORRESP · Letter to the SEC | May 29, 2026 | Other filings | SEC |
| S-3 · Registration statement | May 22, 2026 | Offer document | SEC |
| 8-K · Current report | May 15, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2026 | Material contract | SEC |
| 8-K · Current report | Apr 29, 2026 | Financing | SEC |
| 8-K · Current report | Apr 24, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Apr 24, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 6, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Mar 31, 2026 | Current report | SEC |
| 8-K · Current report | Mar 10, 2026 | Current report | SEC |
| 8-K · Current report | Mar 4, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Feb 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Feb 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Feb 24, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Feb 13, 2026 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Jan 28, 2026 | Annual report | SEC |
| 8-K · Current report | Dec 23, 2025 | Results | SEC |
| 10-K · Annual report | Dec 23, 2025 | Annual report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 1, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Oct 23, 2025 | Current report | SEC |
| 8-K · Current report | Oct 21, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 21, 2025 | Offer document | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 25, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 8, 2025 | Current report | SEC |
| 8-K · Current report | Jun 12, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jun 11, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 9, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 3, 2025 | Material contract | SEC |
| 8-K · Current report | May 30, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 18, 2025 | Material contract | SEC |
| 8-K · Current report | Apr 3, 2025 | Material contract | SEC |
| 8-K · Current report | Apr 2, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Apr 2, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 10, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Feb 14, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Feb 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Feb 6, 2025 | Current report | SEC |
| 10-K/A · Annual report, amended | Jan 27, 2025 | Annual report | SEC |
| ARS · Annual report to shareholders | Jan 27, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jan 27, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jan 27, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jan 16, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jan 8, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jan 8, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 7, 2025 | Current report | SEC |
| 8-K · Current report | Dec 27, 2024 | Results | SEC |
| 10-K · Annual report | Dec 27, 2024 | Annual report | SEC |
| 8-K · Current report | Dec 20, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 27, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 26, 2024 | Current report | SEC |
| 8-K · Current report | Nov 25, 2024 | Current report | SEC |
| 8-K · Current report | Nov 18, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Nov 18, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 13, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 12, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 27, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 13, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 11, 2024 | Current report | SEC |
| 8-K · Current report | Sep 5, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 16, 2024 | Material contract | SEC |
| SC 13D · Big-stake notice | Aug 16, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 424B5 · Prospectus | Aug 12, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Current report | SEC |
| 8-K · Current report | May 21, 2024 | Current report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | May 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Apr 30, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Apr 26, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 5, 2024 | Current report | SEC |
| 4 · Change in ownership | Apr 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 18, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | Mar 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 13, 2024 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Mar 4, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 29, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 29, 2024 | Other filings | SEC |
| S-3 · Registration statement | Feb 23, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 23, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 15, 2024 | Results | SEC |
| 10-Q · Quarterly report | Feb 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Feb 14, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Jan 31, 2024 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Jan 26, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jan 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jan 26, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jan 23, 2024 | Current report | SEC |
| 8-K · Current report | Jan 5, 2024 | Current report | SEC |
| 8-K · Current report | Jan 2, 2024 | Results | SEC |
| 10-K · Annual report | Dec 29, 2023 | Annual report | SEC |
| 425 | Oct 24, 2023 | Other filings | SEC |
| 8-K · Current report | Oct 24, 2023 | Material contract | SEC |
| 4 · Change in ownership | Oct 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 12, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 25, 2023 | Current report | SEC |
| 8-K · Current report | Sep 15, 2023 | Current report | SEC |
| 8-K · Current report | Sep 11, 2023 | Current report | SEC |
| 8-K · Current report | Sep 8, 2023 | Current report | SEC |
| 8-K · Current report | Aug 15, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2023 | Current report | SEC |
| 8-K · Current report | Jul 31, 2023 | Current report | SEC |
| 8-K · Current report | Jun 29, 2023 | Current report | SEC |
| 8-K · Current report | Jun 20, 2023 | Current report | SEC |
| 8-K · Current report | May 12, 2023 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2023 | Material contract | SEC |
| 424B5 · Prospectus | May 5, 2023 | Offer document | SEC |
| 8-K · Current report | Apr 24, 2023 | Current report | SEC |
| 8-K · Current report | Apr 3, 2023 | Current report | SEC |
| S-8 · Registration statement for employee plans | Feb 10, 2023 | Offer document | SEC |
| 8-K · Current report | Feb 10, 2023 | Results | SEC |
| 10-Q · Quarterly report | Feb 10, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Feb 9, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 9, 2023 | Insider trade | SEC |
| 8-K · Current report | Feb 7, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Dec 22, 2022 | Results | SEC |
| DEFA14A · Additional proxy material | Dec 22, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Dec 22, 2022 | Meeting notice | SEC |
| 10-K · Annual report | Dec 22, 2022 | Annual report | SEC |
| 8-K · Current report | Dec 1, 2022 | Current report | SEC |
| 8-K · Current report | Nov 21, 2022 | Current report | SEC |
| 4/A · Change in ownership, amended | Nov 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2022 | Insider trade | SEC |
| 8-K · Current report | Sep 28, 2022 | Current report | SEC |
| 8-K · Current report | Sep 22, 2022 | Current report | SEC |
| 8-K · Current report | Aug 11, 2022 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2022 | Quarterly report | SEC |
| 25-NSE | Aug 8, 2022 | Other filings | SEC |
| 8-K · Current report | Jul 12, 2022 | Current report | SEC |
| SC 13G · Big-stake notice | Jul 8, 2022 | Big-stake notice | SEC |
| 8-K · Current report | May 25, 2022 | Current report | SEC |
| 8-K · Current report | May 12, 2022 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2022 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2022 | Current report | SEC |
| 8-K · Current report | Apr 26, 2022 | Current report | SEC |
| 8-K · Current report | Apr 13, 2022 | Management or board change | SEC |
| 8-K · Current report | Apr 6, 2022 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 18, 2022 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 18, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Feb 15, 2022 | Current report | SEC |
This page holds 200 of 638 filings. Open Filings
Cap table
Built by 6ix from Citius Pharmaceuticals, Inc.’s releases · as of Aug 13, 2026
- Common shares
- 27,452,570
- Fully diluted
- 27,452,570
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 27,452,570 | Aug 13, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.86 · expire about Apr 2031 |
| Warrants · US$1.40 · expire about Oct 2030 |
| Warrants · US$1.00 · expire about Jun 2027 |
Share count over time
| Count | Shares |
|---|---|
| Aug 13, 2026 | 27,452,570 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Dennis M. McGrath Other companies: Citius Oncology, Inc. (Director · Since at least Aug 12, 2024); Lucid Diagnostics Inc. (Chief Financial Officer · Since at least Oct 13, 2021); PAVmed Inc. (President and CFO · Since at least Feb 14, 2018); DarioHealth Corp. (Board Member · Since at least Oct 23, 2017) | Director · Since at least Feb 7, 2023 |
| Leonard Mazur Other companies: Citius Oncology, Inc. (Chairman · Since at least Aug 12, 2024); Canton Strategic Holdings, Inc. (Director · Jan 11, 2022 – Aug 9, 2024 · Past) | Co-Founder, CEO and Chairman of the Board of Directors · Since at least Mar 30, 2016 |
| Myron Holubiak Other companies: Citius Oncology, Inc. (Secretary · Since at least Aug 12, 2024); Assembly Biosciences, Inc. (Director · May 30, 2018 – May 20, 2021 · Past) | Co-Founder, Executive Vice Chairman · Since at least Mar 28, 2018 |
| Carol Webb Other companies: Citius Oncology, Inc. (Director · Since at least Nov 5, 2026) | Director · Since at least Nov 5, 2026 |
| Eugene Holuka Other companies: Citius Oncology, Inc. (Director · Since at least Aug 12, 2024) | Director · Since at least Oct 6, 2020 |
| Howard Safir Other companies: Verint Systems Inc (Director · Apr 20, 2018 – Apr 20, 2021 · Past) | Director · Sep 4, 2018 – Oct 4, 2022 · Past |
| Jaime Bartushak Other companies: Citius Oncology, Inc. (Chief Financial Officer · Since at least Aug 12, 2024) | Chief Financial Officer & Chief Business Officer · Since at least Oct 6, 2020 |
| Myron S. Czuczman Other companies: Citius Oncology, Inc. (Chief Medical Officer · Since at least Aug 12, 2024) | Chief Medical Officer and EVP · Since at least Jul 14, 2020 |
| Robert Smith Other companies: Citius Oncology, Inc. (Director · Since at least Aug 12, 2024) | Director · Since at least Mar 12, 2024 |
| Suren Dutia Other companies: Citius Oncology, Inc. (Director · Since at least Nov 5, 2026) | Director · Since at least Nov 5, 2026 |
All 19 people
| Person | Seat |
|---|---|
| Alan Lader | SVP, Head of Clinical Operations and Quality Assurance · Since at least Nov 5, 2026 |
| Catherine Kessler | EVP, Regulatory Affairs · Since at least Nov 5, 2026 |
| Gary F. Talarico | EVP, Operations · Since at least Nov 5, 2026 |
| Jay Wadekar | SVP, Business Strategy · Since at least Nov 5, 2026 |
| Kelly Creighton | EVP, Chemistry, Manufacturing and Controls · Since at least Nov 5, 2026 |
| Kevin Carey | VP, Program & Alliance Management · Since at least Nov 4, 2026 |
| Michael McGuire | VP, Commercial · Since at least Jul 21, 2026 |
| Nikolas Burlew | EVP, Quality Assurance · Since at least Nov 5, 2026 |
| William Kane | Director · Oct 6, 2020 – Oct 4, 2022 · Past |
Log in to ask 6ix AI your own questions about Citius Pharmaceuticals, Inc.